Unituxin approved for deadly pediatric cancer
(HealthDay)—Unituxin (dinutuximab) has been approved by the U.S. Food and Drug Administration to treat children with high-risk neuroblastoma, a rare cancer that most often affects children aged five and under.
Mar 11, 2015
0
6